ARCHIVES

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

Advocates Call For Metrics And Action Plan In NCI’s Redesign of Cooperative Groups

July 8, 2011

Committee Discusses Cap On Center Grants, New Guidelines

October 18, 1991

PDQ Needs Change, Advocates Say, NBCC to Build Its Own Trials Registry

October 11, 1996

New Drug Approvals Point To Greater Role Of Randomization In Cancer Clinical Trials. European Standards Will Demand More Rigor.

February 24, 2006

Women’s Health: Treatment to Move Toward Pre-Cancer, Klausner Says

December 5, 1997

Conversation With The Cancer Letter: How ASCO’s Guideline Differs—And Why

July 20, 2012